Your browser doesn't support javascript.
loading
Neurofibromatosis type I: mutation spectrum of NF1 in spanish patients.
Palma Milla, Carmen; Lezana Rosales, José Miguel; López Montiel, Javier; Andrés Garrido, Lucas David; Sánchez Linares, Carlos; Carmona Tamajón, Sandra; Torres Fernández, Carmen; Sánchez González, Pablo; Franco Freire, Sara; Benito López, Carmen; López Siles, Juan.
Afiliación
  • Palma Milla C; C.G.M Genetaq, Málaga, Spain.
  • Lezana Rosales JM; C.G.M Genetaq, Málaga, Spain.
  • López Montiel J; C.G.M Genetaq, Málaga, Spain.
  • Andrés Garrido LD; C.G.M Genetaq, Málaga, Spain.
  • Sánchez Linares C; C.G.M Genetaq, Málaga, Spain.
  • Carmona Tamajón S; C.G.M Genetaq, Málaga, Spain.
  • Torres Fernández C; C.G.M Genetaq, Málaga, Spain.
  • Sánchez González P; C.G.M Genetaq, Málaga, Spain.
  • Franco Freire S; Hospital Regional Universitario de Málaga. U.G.C. de Laboratorio. Sección de Genética.
  • Benito López C; Hospital Regional Universitario de Málaga. U.G.C. de Laboratorio. Sección de Genética.
  • López Siles J; C.G.M Genetaq, Málaga, Spain.
Ann Hum Genet ; 82(6): 425-436, 2018 11.
Article en En | MEDLINE | ID: mdl-30014477
ABSTRACT
Neurofibromatosis type I (NF1) is one of the most common genetic disorders in humans. NF1, a tumor predisposition syndrome, is caused by heterozygous pathogenic variants in the NF1 gene. Molecular genetic testing of NF1 is complex, especially because of the presence of a high number of partial pseudogenes, some of them with a high percentage of sequence identity. In this study, we have analyzed the largest cohort of NF1 Spanish patients (150 unrelated individuals suspected of having NF1 and 53 relatives, making a total of 203 individuals). Mutation analysis of the entire coding region was performed in all unrelated index patients. Additionally, the Multiplex Ligation-dependent Probe Amplification (MLPA) test of the NF1 gene and SPRED1 gene analysis (sequencing and MLPA test) was performed in some of the negative patients for NF1 point mutations. When fulfilling the National Institutes of Health (NIH) criterion for the clinical diagnosis of NF1, the detection rate was 79%. Among the 80 genetically confirmed NF1 probands, we detected 69 different pathogenic variants. Two mutations (3%) were gross deletions of the whole gene, the remaining 78 mutations (97%) were small changes spread among all NF1 exons. Among these 69 different mutations detected, 42 mutations were described elsewhere, and 27 mutations were novel mutations. When segregation was studied, 67% of mutations resulted de novo variants. No genetic mosaicism was detected on patients' parents.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neurofibromatosis 1 / Neurofibromina 1 Tipo de estudio: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Ann Hum Genet Año: 2018 Tipo del documento: Article País de afiliación: España

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neurofibromatosis 1 / Neurofibromina 1 Tipo de estudio: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Ann Hum Genet Año: 2018 Tipo del documento: Article País de afiliación: España